MIRA INFORM
REPORT
|
Report Date : |
04.05.2012 |
IDENTIFICATION DETAILS
|
Name : |
APT
PHARMA LTD. |
|
|
|
|
Formerly Known As : |
Apotec
Pharmaceutical Ltd |
|
|
|
|
Registered Office : |
3/F., 4/F. & Unit B, 6/F., |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
21.12.1990 |
|
|
|
|
Com. Reg. No.: |
14304442 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacturer and Exporter of all kinds of pharmaceutical preparations, tablets and capsules, etc. |
|
|
|
|
No. of Employees
: |
65 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment
Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Hong Kong |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
APT PHARMA LTD.
3/F., 4/F., Unit B, 6/F. & Unit A, 12/F., Tai Fung Industrial Building, 61 Hung To Road, Kwun Tong, Kowloon, Hong Kong.
PHONE: 2389
6279, 2341 7878
FAX: 2372 9990, 2341 7070
E-MAIL: michael.ng@apt-pharma.com
General Manager: Mr. Sum Kwong Yip, Derek
Incorporated on: 21st December, 1990.
Organization: Private Limited Company.
Capital: Nominal: HK$8,750,000.00
Issued: HK$8,750,000.00
Business Category: Pharmaceutical Trader.
Employees: 65. (Hong Kong)
Main Dealing Banker: Standard Chartered Bank (Hong Kong) Ltd., Hong Kong.
Banking Relation: Good.
Registered Head
Office:-
3/F., 4/F. & Unit B, 6/F., Tai Fung Industrial Building, 61 Hung To Road, Kwun Tong, Kowloon, Hong Kong.
Branch Office:-
Unit A, 12/F., Tai Fung Industrial Building, 61 Hung To Road, Kwun Tong, Kowloon, Hong Kong.
China Factory:-
APT Pharma (China) Ltd., China.
Holding Company:-
APT Interpharma (BVI) Ltd., British Virgin Islands.
[Formerly known as Jacobson Medical International Holdings Ltd.]
Associated/Affiliated
Companies:-
· Europharm Laboratoires Co. Ltd., Hong Kong.
· Frankin Pharmaceutical Laboratories Co. Ltd., Hong Kong.
· Jacobson Group Management Ltd., Hong Kong.
· Jacobson Medical (Hong Kong) Ltd., Hong Kong.
· Jacobson Pharma (China) Ltd., Hong Kong.
· Jean-Marie Pharmacal Co. Ltd., Hong Kong.
·
Sino Wealth (Far East) Ltd., Hong Kong.
[Formerly known as Jacobson Medical Co. Ltd.]
· Synco (H.K.) Ltd., Hong Kong.
· Synco Pharma Holdings (BVI) Ltd., British Virgin Islands.
· Vickmans International Holdings Ltd., British Virgin Islands.
· Vickmans Laboratories Ltd., Hong Kong.
14304442
0294627
General Manager: Mr. Sum Kwong Yip, Derek
Nominal Share Capital: HK$8,750,000.00 (Divided into 8,750,000 shares of HK$1.00 each)
Issued Share Capital: HK$8,750,000.00
(As per registry dated
21-12-2011)
|
Name |
|
No. of shares |
|
APT Interpharma (BVI) Ltd. [Formerly known as Jacobson Medical International Holdings Ltd.] 263 Main Street, P.O. Box 2196, Road Town, Tortola, British Virgin Islands. |
|
8,750,000 ======= |
(As per registry
dated 21-12-2011)
|
Name |
Address |
|
Ample Wise Nation Ltd. |
263, Main Street, P.O. Box 2196, Road Town, Tortola, British Virgin Islands. |
(As per registry
dated 21-12-2011)
|
Name |
Address |
Co.
No. |
|
Shum Law Corporate Services Ltd. |
Room 1101, 11/F., Wing
Lung Bank Centre, |
0209105 |
The subject was incorporated on 21st December, 1990 as a private limited liability company under the Hong Kong Companies Ordinance.
Originally the subject was registered under the name of Niceth International Ltd., name changed to Apotec International Co. Ltd. on 28th March, 1991; changed to Merck Apotec Ltd. on 16th June, 1999; to Merck Pharmaceutical Ltd. on 14th May, 2003; to Apotec Pharmaceutical Ltd. on 19th January, 2005 and further the present style on 26th July, 2006.
Apart from these, neither material change nor amendment has been ever traced and noted.
Activities: Manufacturer and Exporter.
Lines: All kinds of pharmaceutical preparations, tablets and capsules, etc.
Employees: 65. (Hong Kong)
240. (China)
Commodities Imported: India, Europe, etc.
Markets: Hong Kong, other Asian countries, Southeast Asia, etc.
Terms/Sales: COD or as per contracted.
Terms/Buying: L/C, T/T, D/P, etc.
GOVERNMENT
CONTRACTS AWARDED SINCE 1990:
|
Date |
GN
No. |
Tender
Board – Department |
Amount |
|
25-02-2000 |
GN1206 |
Government Supplies Dept. |
HK$9,024,000 |
|
27-12-2002 |
GN8570 |
Government Supplies Dept. |
HK$437,400 |
|
28-02-2003 |
GN1376 |
Government Supplies Dept. |
HK$2,131,500 |
|
25-07-2003 |
GN5080 |
Government Supplies Dept. |
HK$421,200 |
|
26-03-2004 |
GN2097 |
Government Logistics Dept. |
HK$9,900,000 |
|
26-03-2004 |
GN2097 |
Government Logistics Dept. |
HK$285,750 |
|
30-04-2004 |
GN2833 |
Government Logistics Dept. |
HK$3,420,000 |
|
30-04-2004 |
GN2833 |
Government Logistics Dept. |
HK$844,750 |
|
30-04-2004 |
GN2833 |
Government Logistics Dept. |
HK$674,700 |
|
30-07-2004 |
GN4942 |
Government Logistics Dept. |
HK$1,662,500 |
|
31-12-2004 |
GN8446 |
Government Logistics Dept. |
HK$607,000 |
|
29-04-2005 |
GN2066 |
Government Logistics Dept. |
HK$7,750,000 |
|
27-05-2005 |
GN2517 |
Government Logistics Dept. |
HK$11,200,000 |
|
25-11-2005 |
GN6203 |
Government Logistics Dept. |
HK$738,150 |
|
30-12-2005 |
GN7013 |
Government Logistics Dept. |
HK$219,950 |
|
24-02-2006 |
GN1282 |
Government Logistics Dept. |
HK$711,000 |
|
28-04-2006 |
GN2700 |
Government Logistics Dept. |
HK$1,220,803 |
|
28-04-2006 |
GN2700 |
Government Logistics Dept. |
HK$1,744,400 |
|
28-07-2006 |
GN4724 |
Government Logistics Dept. |
HK$494,100 |
|
29-09-2006 |
GN6327 |
Government Logistics Dept. |
HK$439,350 |
|
29-09-2006 |
GN6327 |
Government Logistics Dept. |
HK$2,296,000 |
|
29-09-2006 |
GN6327 |
Government Logistics Dept. |
HK$3,168,205 |
Nominal Share Capital: HK$8,750,000.00 (Divided into 8,750,000 shares of HK$1.00 each)
Issued Share Capital: HK$8,750,000.00
Indebtedness: HK$25,200,000.00 (Total amount outstanding on all mortgages and charges as per last
Annual Return dated 21-12-2011)
Mortgage or Charge
(since 2012): (See attachment)
Profit or Loss: Business is profitable.
Condition: Keeping in an active and good condition.
Facilities: Making active use of general banking facilities.
Payment: Met trade commitments on time.
Commercial Morality: Satisfactory.
Bankers:-
· Standard Chartered Bank (Hong Kong) Ltd., Hong Kong.
· Hang Seng Bank Ltd., Hong Kong.
· The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
Standing: Good.
APT Pharma Ltd. is a wholly-owned subsidiary of APT Interpharma (BVI) Ltd. which is a BVI-registered firm.
The subject is a pharmaceutical preparation, tablet and capsule manufacturer and trader. Currently, the subject is manufacturing the following commodities and offering clients with the following services:-
|
Product/Service |
Product/Service
Remarks |
|
Pharmaceutical and Medicine |
|
|
Pharmaceutical Preparation |
Syrup and suspension – pharmaceutical |
|
Tablet and Capsule – Pharmaceutical |
Gelatin/sugar coated/foilpack |
|
Ointment – Pharmaceutical |
|
The subject’s manufacturing plant is in Hong Kong. Besides the Hong Kong plant, the subject has had a factory in China.
The subject’s factory in China is known as APT Pharma (China) Ltd. [China APT] which is in Zhongshan City, Guangdong Province, China. With a registered capital of RMB80 million Yuan, China APT is employing about 240 persons. The total investment of China APT was about RMB120 million Yuan. About 90% of the pharmaceuticals are marketed in Hong Kong and exported to Southeast Asia.
The subject is closely related to Merck which is a Germany-based pharmaceutical firm. In June 1999, Merck acquired 60% stake of China APT from the subject by making an investment of over HK$80 million.
So far, Merck has been a large business partner of the subject.
The followings are the main products of the subject which has been registered with the Hong Kong SAR Government:-
· Enalapril Maleate Tab 10 mg
· Enalapril Maleate Tab 20 mg
· Enalapril Maleate Tab 5 mg
The following firms are the main associated companies of the subject:-
Europharm Laboratories Co. Ltd. [Europharm]
Frankin Pharmaceutical Laboratories Co. Ltd.
Jacobson Medical (Hong Kong) Ltd. [Jacobson]
Jean-Marie Pharmacal Co. Ltd.
Vickmans Laboratories Ltd.
Europharm was founded in July 1986. It is the largest drug supplier in Hong Kong in terms of volume. Europharm now has more than 100 employees, who are responsible for production, quality control, quality assurance, sales and marketing, engineering and administration respectively. In its manufacturing plant, Europharm has clean rooms for production, thermo-regulated warehouse and a series of laboratories. All facilities are planned and designed by the Hong Kong Institute of Biotechnology [HKIB].
Mr. Derek Sum Kwong Yip, aged 48, is a qualified pharmacist from the United Kingdom and currently holds the qualifications of B. Pharm (Hons) and MRPS (UK). Mr. Sum has had extensive experience in the healthcare industry and has previously held a number of senior management positions with various multi-national corporations. He is the Managing Director of Jacobson. He has a 15% stake in this company. Sum is also the CEO of Europharm.
Europharm is one of the main pharmaceutical suppliers of Hong Kong Hospital Authority [HKHA] which is administering all the hospitals in Hong Kong. Every year, HKHA purchases pharmaceuticals by calling for bids. Usually Europharm is able to get about 20% of the contracted value offered by HKHA.
The subject’s total amount outstanding registered with the Companies Registry as at late December 2011 amounted to HK$25.2 million.
The subject has been a significant pharmaceutical company. History in Hong Kong is over twenty-one years and three months.
On the whole, consider it good for normal business engagements.
REMARKS:
Property information of the company:-
1. Property Location: 3/F., Tai Fung Industrial Building, 61 Hung To Road, Kowloon, Hong Kong.
Owner: APT Pharma Ltd.
Date of Purchase: n.a.
Purchased Price: n.a.
Incumbrances:-
|
Date of Mortgage |
Amount Consideration |
Mortgagee |
Nature |
|
07-10-2005 |
- |
Standard Chartered Bank (Hong Kong) Ltd., Hong Kong. |
Mortgage to secure general banking facilities |
2. Property Location: Unit
A (including Flat Roof appurtenant thereto) on 4/F.,
Tai Fung Industrial Building, 61 Hung To Road, Kowloon, Hong Kong.
Owner: APT Pharma Ltd.
Date of Purchase: n.a.
Purchased Price: n.a.
Incumbrances:-
|
Date of Mortgage |
Amount Consideration |
Mortgagee |
Nature |
|
28-10-2008 |
- |
Standard Chartered Bank (Hong Kong) Ltd., Hong Kong. |
Mortgage to secure general banking facilities granted to Europharm Laboratoires Co. Ltd., Jacobson Medical (Hong Kong) Ltd., Vickmans Laboratories Ltd., APT Pharma Ltd. and Synco (H.K.) Ltd. |
3. Property Location: Unit A on 6/F., Tai Fung Industrial Building, 61 Hung To Road, Kowloon, Hong Kong.
Owner: APT Pharma Ltd.
Date of Purchase: n.a.
Purchased Price: n.a.
Incumbrances:-
|
Date of Mortgage |
Amount Consideration |
Mortgagee |
Nature |
|
28-10-2010 |
- |
The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong. |
Mortgage to secure general banking facilities |
4. Property Location: Unit
A & B on 10/F., Tai Fung Industrial Building,
61 Hung To Road, Kowloon, Hong Kong.
Owner: APT Pharma Ltd.
Date of Purchase: n.a.
Purchased Price: n.a.
Incumbrances:-
|
Date of Mortgage |
Amount Consideration |
Mortgagee |
Nature |
|
31-07-2009 |
- |
Standard Chartered Bank (Hong Kong) Ltd., Hong Kong. |
Mortgage to secure general banking facilities granted to Europharm Laboratoires Co. Ltd., Jacobson Medical (Hong Kong) Ltd., Vickmans Laboratories Ltd., APT Pharma Ltd. and Synco (H.K.) Ltd. |
5. Property Location: Car Parking Space No. P3 on G/F., Tai Fung Industrial
Building,
61 Hung To Road, Kowloon, Hong Kong.
Owner: APT Pharma Ltd.
Date of Purchase: n.a.
Purchased Price: n.a.
Incumbrances:-
|
Date of Mortgage |
Amount Consideration |
Mortgagee |
Nature |
|
23-12-2005 |
- |
Standard Chartered Bank (Hong Kong) Ltd., Hong Kong. |
Mortgage to secure general banking facilities |
(Since 2012)
|
Date |
Particulars |
Amount |
|
22-02-2012 |
Instrument: Assignment of Life Insurance Property: Property Charged: (i) all the Assignor’s claims, options, privileges, right, title, interest and benefit in and under the Insurance; and (ii) all the Assignor’s claims and rights against the issuer of the Policy (No. 28004677) in respect of the Policy upon the terms Mortgagee: The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong. |
Secured Monies |
|
22-02-2012 |
Instrument: Assignment of Life Insurance Property: Property Charged: (i) all the
Assignor’s claims, options, privileges, right, title, interest and benefit in
and under the Insurance; and (ii) all the Assignor’s claims and rights
against the issuer of the Policy (No. 28004674) in respect of the Policy upon the terms Mortgagee: The
Hongkong & Shanghai Banking Corp. Ltd., Hong Kong. |
Secured Monies |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.23 |
|
UK Pound |
1 |
Rs.86.14 |
|
Euro |
1 |
Rs.69.98 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.